GlassScriptPhysician profile
Daniel L Hofius
NPI 1356301311
$2,755.46
in general payments reported to CMS, 2019-2025
31 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $27.92 · 2021: $40.36 · 2022: $398 · 2023: $138 · 2024: $1,251 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.22 | 2021-2025 | |
| Novo Nordisk INC | $279.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $268.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $237.77 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $177.11 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $168.02 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $146.52 | 2022-2025 | |
| Astellas Pharma US INC | $127.41 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $112.75 | 2019-2025 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $97.06 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $93.92 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $78.61 | 2024 | Injectafer |
| Ethicon US, LLC | $68.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $67.22 | 2022-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $54.31 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.45 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $47.65 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $44.91 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $44.84 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $40.39 | 2024-2025 | Camzyos, Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $37.23 | 2022 | |
| Mylan Specialty L.P. | $34.89 | 2024 | Yupelri |
| Antares Pharma, INC. | $25.00 | 2024 | Xyosted |
| Harmony Biosciences LLC | $24.23 | 2023 | Wakix |
| Hologic Sales and Service, LLC | $21.94 | 2023 | Thinprep 2000 Processor |
| Sanofi Pasteur INC. | $20.82 | 2022 | |
| Inspire Medical Systems, INC. | $20.25 | 2024 | Inspire |
| Cranial Technologies, INC | $17.50 | 2022 | |
| Medtronic, INC. | $15.32 | 2022 | |
| Viatris Specialty LLC | $14.15 | 2025 | Yupelri |
| Boston Scientific Corporation | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hofius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.